deltatrials
Active Not Recruiting PHASE4 INTERVENTIONAL 3-arm NCT06627530

COACTION Trial - COmbination Androgen bloCkade in inTermediate to hIgh-risk prOstate caNcer (COAction)

A Randomized Trial of Neoadjuvant Leuprorelin, Darolutamide or Both Prior to Radical Prostatectomy for Intermediate or High-risk Prostate Cancer

Sponsor: Bayer

Conditions Prostate Cancer
Interventions Darolutamide Oral Tablet leuprorelin
Updated 3 times since 2024 Last updated: Feb 10, 2026 Started: Feb 17, 2025 Primary completion: Mar 31, 2026 Completion: Sep 30, 2026
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT06627530, this PHASE4 trial focuses on Prostate Cancer and remains ongoing. Sponsored by Bayer, it has been updated 3 times since 2025, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Nov 2024 – ~Jun 2025 · 7 months · monthly snapshotNot Yet Recruiting~Jun 2025 – ~Feb 2026 · 8 months · monthly snapshotRecruiting~Feb 2026 – present · 5 months · monthly snapshotActive Not Recruiting

Change History

3 versions recorded

  1. Feb 2026 — Present [monthly]

    Active Not Recruiting PHASE4

    Status: Recruiting → Active Not Recruiting

  2. Jun 2025 — Feb 2026 [monthly]

    Recruiting PHASE4

    Status: Not Yet Recruiting → Recruiting

  3. Nov 2024 — Jun 2025 [monthly]

    Not Yet Recruiting PHASE4

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Bayer
  • Brazilian Clinical Research Institute
Data source: Brazilian Clinical Research Institute

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations